Pilot Study of Terazosin in Treatment of Antidepressant Induced Excessive Sweating
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||A Pilot Study of the Efficacy and Tolerability of Terazosin for the Treatment of Antidepressant-Induced Excessive Sweating|
- To study whether terazosin 1 to 5 mg/ day is effective in reducing antidepressant-induced sweating
- To determine if terazosin is tolerated and acceptable to patients as a potential treatment for antidepressant-induced sweating
- Determine the time-course of response, the dose-response relationship, and the magnitude of effect of treatment of antidepressant-induced sweating to assist in designing a subsequent double-blind, placebo-controlled study of this treatment.
|Study Start Date:||May 2005|
|Study Completion Date:||May 2007|
|Primary Completion Date:||May 2006 (Final data collection date for primary outcome measure)|
Sweating is a common and bothersome side effect of treatment with antidepressants. Most or all antidepressants have been clearly shown to cause excessive sweating. It is unclear to what extent excessive sweating caused by antidepressants becomes less or goes away with time. In many instances, it continues to be a problem even after 6 or more months on the antidepressant.
There is no generally accepted treatment for excessive sweating. This study has been designed to study whether terazosin is effective in reducing antidepressant-induced sweating, and whether it is well-tolerated and acceptable to patients. In addition, secondary objectives of this study are to determine the time taken for patients to respond to terazosin, the usual doses needed for improvement, and the extent of reduction in sweating. This information will not only help doctors in using terazosin for this purpose in their patients, but will help in designing further studies of this treatment.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00237510
|United States, Pennsylvania|
|Thomas Jefferson University Department of Psychiatry and Human Behavior|
|Philadelphia, Pennsylvania, United States, 19107|
|Principal Investigator:||Rajnish Mago, MD||Thomas Jefferson University Department of Psychiatry and Human Behavior|